ArticleClinical hematology international2026
Secondary failure of platelet recovery after allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia: Incidence, risk factors, and clinical outcomes.
Article in Clinical hematology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary failure of platelet recovery (SFPR) poses a significant risk for life-threatening complications following hematopoietic stem cell transplantation (HSCT). However, the incidence, clinical outcomes, and risk factors associated with SFPR in the context of allogeneic HSCT (allo-HSCT) for pediatric patients with acquired aplastic anemia (AA) remain unclear. We conducted a retrospective review of 86 consecutive acquired AA children who underwent allo-HSCT at our center from December 2017 to November 2023. The 1-year cumulative incidence of SFPR was found to be 11.6% (95% confidence interval [CI]: 6.2%-21.1%). The median time to SFPR was 2 months (range: 1-5 months) post-transplantation. To clarify the risk factors for SFPR, 9 SFPR cases and 69 non-SFPR cases were further analyzed. Multivariable analyses revealed that age, pre-transplantation body mass index (BMI) and a history of grade Ⅲ-Ⅳ acute graft-versus-host disease (aGVHD) were the most significant predictors for SFPR post-transplantation (p < 0.05). Additionally, we found that the 2-year overall survival rate was significantly lower in children with SFPR compared to those without (74.1% vs. 96.7%; p < 0.005). Ultimately, 4 patients achieved full platelet count recovery, with 2 patients becoming transfusion-independent. However, 1 patient still requires periodic platelet transfusions, and 2 patients unfortunately died.Among the 6 patients who received thrombopoietin receptor agonist therapy, an overall response rate of 66.6% was observed, suggesting the potential efficacy of this treatment approach in managing SFPR. This study underscores the need for vigilant monitoring of platelet recovery in pediatric HSCT recipients and highlights the need for further research into the etiology of SFPR to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.